

Ending Cancer As We Know It – For All

Douglas R. Lowy, M.D.
Acting Director, National Cancer Institute

*17th Virtual Meeting of the National Cancer Advisory Board
August 31, 2022*

@NCIDirector
@TheNCI

Today's talk

- Some NCI News
 - New Director
 - Annual Plan
- Scientific Updates
- Cancer Moonshot
- Frederick National Lab programs

White House to Appoint New NCI Director Dr. Monica Bertagnolli



BRIEFING ROOM

President Biden Intends to Appoint Dr.
Monica Bertagnolli as Director of the
National Cancer Institute

AUGUST 10, 2022 • STATEMENTS AND RELEASES



Coming Soon:
Annual Plan & Budget Proposal for FY 2024

Highlighted Scientific Opportunities:

Multi-cancer detection tests


Undruggable targets

Cell Therapy

Persistent Poverty

Coming soon: cancer.gov/research/annual-plan

President's NCI Budget and Enacted Appropriations




Source: NCI Budget Fact Book

- Strong bipartisan support for cancer research across Congress
- Congress has declined to cut funding to cancer research – even in challenging budget cycles

New study: Many types of physical activity may lower risk of death for older adults

For older adults (age 59-82) getting 7.5-15 MET/week of physical activity, risk of death decreased – *regardless of type of activity.*




Watts EL, et al. Association of Leisure Time Physical Activity Types and Risks of All-Cause, Cardiovascular, and Cancer Mortality Among Older Adults. *JAMA Network Open*. August 24, 2022.

Pembrolizumab Improves Survival in Advanced Triple-Negative Breast Cancer

Adding pembrolizumab (an immunotherapy) to chemotherapy can help some patients with advanced triple-negative breast cancer live longer, compared to receiving chemotherapy alone.


FDA approved the combination therapy in 2020 for patients whose tumors have high levels of PD-L1 protein.



Cortes J, et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. *New England Journal of Medicine*. July 21, 2022.

Smoking Cessation in Cancer Patients

NCI Tobacco Control Monograph 23 (June 2022)




Smoking cessation in cancer patients is among the most effective treatment options for:

- improving the likelihood of survival,
- quality of life, and
- overall health of cancer patients who smoke.

It is important for cancer care clinicians and patients to realize:

- It is *never too late* to quit smoking.
- There are *clear benefits* to quitting smoking – *regardless of cancer type*.

Number of Cancer Survivors in U.S. Grows to 18M



- **18.1 million cancer survivors** in the U.S. (as of January 2022)
- **26 million by 2040** (projected)
- More than **two-thirds are 65+**



For more: Miller KD, et al. Cancer treatment and survivorship statistics, 2022. *CA: A Cancer Journal for Clinicians*. June 23, 2022.

Cancer Cabinet Meeting (July 13, 2022)



BRIEFING ROOM

FACT SHEET: President Biden Appoints Cancer Panel Members and Cancer Cabinet Unveils Priority Actions

JULY 13, 2022 • STATEMENTS AND RELEASES

*Details at:
[whitehouse.gov/briefing-room](https://www.whitehouse.gov/briefing-room)*

PRIORITY ACTIONS FOR THE CANCER CABINET

1. Close the Screening Gap
2. Understand and Address Environmental and Toxic Exposures
3. Decrease the Impact of Preventable Cancers
4. Bring Cutting Edge Research Through the Pipeline to Patients and Communities
5. Support Patients and Caregivers

President's Cancer Panel: **New Members**

Advisors to the U.S. President on the National Cancer Program



Elizabeth M. Jaffee, MD (Chair)

Sidney Kimmel Comprehensive
Cancer Center,
Johns Hopkins University



Carol L. Brown, MD, FACOG, FACS

Memorial Sloan Kettering
Cancer Center



Mitchel S. Berger, MD

Brain Tumor Center,
University of California,
San Francisco

President's Cancer Panel: **Current Members**

Advisors to the U.S. President on the National Cancer Program



John P. Williams, MD, FACS (Chair)

Breast Cancer School for Patients,
George Mason University,
Novant-UVA Breast Center



**Edith Peterson Mitchell,
MD, MACP, FCPP, FRCP**

Sidney Kimmel Cancer Center at
Thomas Jefferson University



Robert A. Ingram

Hatteras Venture Partners

Cancer Moonshot Next Phase

Jumpstarting Three Programs



**MOONSHOT SCHOLARS
PROGRAM**



TELEHEALTH



MULTI-CANCER DETECTION


NCI Press Release

NCI awards \$23 million to establish centers of excellence to study telehealth for cancer care

Posted: August 18, 2022

Contact: [NCI Press Office](#)
240-760-6600

NCI, part of the National Institutes of Health, will award \$23 million to four academic institutions to establish centers of excellence that will conduct research on the role of telehealth in delivering cancer-related health care, a practice that became more prevalent during the COVID-19 pandemic.



Credit: iStock

The awards will establish NCI's Telehealth Research Centers of Excellence (TRACE) initiative, which is being supported by the Cancer MoonshotSM, a White House initiative first launched in 2016 and reignited by President Biden in 2022 to accelerate the rate of progress against cancer. The awards are to be distributed over five years, pending availability of funds.

"One of the Cancer Moonshot goals is to make the cancer experience less burdensome for patients and their families and caregivers," said Katrina Goddard, Ph.D., director of NCI's Division of Cancer Control and Population Sciences (DCCPS). "We are awarding these centers of excellence to better understand how telehealth can contribute to improved health outcomes across the cancer care continuum."

Read more at: cancer.gov/news-events

Increasing enrollment of underrepresented groups to NCI clinical trials: *A long-term commitment*

NCI Clinical Trials

NCORP: NCI Community Oncology Research Program

NCTN: NCI's National Clinical Trials Network

1999-2001	2017-2019
14% minority	25% minority

- Most of the increase has been in Black/African American and Hispanic populations

Increasing enrollment of underrepresented groups to NCI clinical trials: New phase of Cancer Moonshot



Goal: Mimic at-risk population for the specific cancer studied



Need **greater investment** (e.g., community engagement)



More diversity among health care providers

NCI Summit on Increasing Diversity, Equity and Inclusion in Early Phase Clinical Trials (Nov. 16, 2022)

Aim: Identify and discuss the implementation of best practices for increasing inclusion and equity in NCI cancer clinical trials.

Hosted by NCI Equity & Inclusion Program
November 16, 2022

Registration information forthcoming at
cancer.gov and Twitter (@theNCI)



Session topics (tentative):

- ✓ Regulatory expectations and policies for increasing diversity in clinical trials
- ✓ DEI success stories
- ✓ Hearing from community health workers and patient advocates
- ✓ Partnerships to promote equity and inclusion in NCI trials

Monkeypox Virus Treatment Trial: Tecovirimat


Primary objective: To evaluate safety and efficacy of Tecovirimat (TPOXX) for patients with Monkeypox disease.

A government-to-government research collaboration: NIAID + DRC Ministry of Public Health.




Study sites: Remote areas in DRC (Democratic Republic of Congo)

Study timeline:



Frederick National Laboratory Partnerships

Academic Partnerships



Partnerships with HBCUs (Historically Black Colleges and Universities)

- Research seminars at Howard University and Frederick National Laboratory (FNL)
- Four summer interns from Morehouse School of Medicine joined FNL, were supported by the American Cancer Society
- Howard University graduate recently joined FNL for post-doctoral training
- More partnerships underway



Photo: Dr. Ethan Dmitrovsky (FNL Director) and Dr. James Lillard (Senior Associate Dean, Morehouse School of Medicine) at AACR

Delegation Visits NCI Frederick (July 22, 2022)

HHS Secretary Xavier Becerra and HHS Region 3 Director Dr. Ala Stanford
Senators Ben Cardin and Chris Van Hollen and Rep. David Trone



From left to right: Carrie Bonomi, Dr. Melinda Hollingshead, Sec. Becerra, Rep. Trone, Dr. Stanford, Sen. Van Hollen, Sen. Cardin, Dr. Lowy, Kelly Dougherty



Thank you!

www.cancer.gov

www.cancer.gov/espanol

1-800-4-CANCER

NCInfo@nih.gov

[@NCIDirector](#)

[@TheNCI](#)



NATIONAL
CANCER
INSTITUTE